US 11220535
Anti-BCMA chimeric antigen receptors
granted A61KA61K2039/505A61K2239/46
Quick answer
US patent 11220535 (Anti-BCMA chimeric antigen receptors) held by Cartesian Therapeutics, Inc. expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cartesian Therapeutics, Inc.
- Grant date
- Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955